Semaglutide tablets brands: which one is which, and what does each do?

The biggest myth: Rybelsus and Wegovy tablets are the same thing in different packaging

This is probably the most common misconception about oral semaglutide, and it is worth correcting at the outset. Yes, both Rybelsus and Wegovy tablets contain semaglutide co-formulated with an absorption enhancer called SNAC. The mechanism that gets semaglutide across the gut lining is the same. But the similarity stops there.

Rybelsus is licensed for blood-sugar control in adults with type 2 diabetes. Its dose range (3 mg, 7 mg, 14 mg) reflects a diabetes therapeutic target. Wegovy tablets are licensed specifically for weight management in adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. Its dose range is entirely separate: 1.5 mg, 4 mg, 9 mg, and a 25 mg maintenance dose. Those 3 mg, 7 mg and 14 mg steps you might read about elsewhere are Rybelsus doses; they are not part of the Wegovy weight-loss tablet ladder and should not be described as such.

Prescribing one for the purpose of the other is off-label, clinically unvalidated for weight loss purposes, and not what the MHRA has authorised. If you are researching oral semaglutide for weight loss, the relevant brand is Wegovy tablets. Full stop.

What Wegovy tablets are, and what the trial evidence actually showed

The MHRA approved Wegovy tablets on 11 June 2026, a meaningful regulatory moment: it made the UK the first European country to license an oral GLP-1 receptor agonist for weight management. Novo Nordisk manufactures them; the active ingredient is semaglutide, the same molecule found in the weekly Wegovy injection, reformulated for once-daily oral use.

The phase 3 trial behind the approval was OASIS 4. It enrolled 307 adults living with obesity or overweight plus at least one weight-related condition, ran for 64 weeks, and compared Wegovy tablets against placebo alongside lifestyle changes. On average, participants taking the tablet lost around 13.6% of their body weight, against roughly 2.4% on placebo. Among those who stayed fully adherent to treatment throughout the trial, average loss was closer to 17%, a figure worth understanding in context rather than treating as the headline number. The most commonly reported side effects were gastrointestinal: nausea, diarrhoea, and constipation, reported in around 74% of participants, typically mild to moderate in severity and settling as the dose titrated. You can read more about the approval on the MHRA's GOV.UK news pages alongside related semaglutide announcements.

No refrigeration is needed, Wegovy tablets store at room temperature, which matters for anyone who travels regularly or finds keeping injectables in the fridge door a practical barrier. The daily routine is specific: first thing in the morning, on an empty stomach, with a small sip of plain water (up to around 120 ml). Then wait at least 30 minutes before any food, drink, or other oral medicines. That means before the kettle goes on, before coffee, before breakfast.

How Rybelsus fits into this, and why it is a separate conversation

Rybelsus (also Novo Nordisk) was licensed in the UK for type 2 diabetes management well before Wegovy tablets arrived. Clinicians use it to improve glycaemic control, and it does that job effectively. Some people with type 2 diabetes who take Rybelsus do lose weight as a secondary effect (that is consistent with how semaglutide works as a GLP-1 receptor agonist) but weight loss is not its licensed indication.

If someone has type 2 diabetes and wants to discuss whether Rybelsus or a weight-management medicine is most appropriate for them, that is a conversation for a prescriber who can see the full clinical picture. For more on why these two brands are not equivalent, the oral semaglutide brand name page goes into the naming history in detail. And if you are curious about whether both could theoretically be taken at once, the clinical guidance on taking Rybelsus and Wegovy together explains why that is not appropriate.

Eligibility, cost context, and what a private consultation involves

For Wegovy tablets, the licensed eligibility criteria are adults with a BMI of 30 or above, or between 27 and 29.9 alongside a qualifying weight-related condition such as high blood pressure, prediabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine suitability, a prescriber also considers your medical history, current medications, and any contraindications before making a decision.

Wegovy tablets are not currently available through the NHS for weight management; a NICE appraisal would be required first. That makes a private prescription the only legal route right now. What Wegovy tablets cost privately varies by provider and is something to weigh against what that price actually includes, consultation, clinical review, delivery, and ongoing support are not always bundled together. For a broader look at the semaglutide tablets treatment category, including how the injection and tablet formulations compare, that page covers the ground in one place.

The NHS medicines information page on semaglutide is a reliable starting point for understanding the medicine itself, side effects, how it works, and what to do if something concerns you. If you think Wegovy tablets might be suitable, check your eligibility with our prescribers through a free consultation; a named clinician, not a piece of software, reads your answers and responds the same day.